RESUMO
AIM: To investigate the relationship between the alterations of complete blood counts and tumor shrinkage during tumor rejection induced by a high dose of 5-FU in C57BL/6 mice. METHODS: Wild type C57BL/6 tumor-bearing mice were treated with different doses of 5-FU intraperitoneally. 75 mg/kg 5-FU was the minimal effective dose of 5-FU that could cure the tumor-bearing mice. Then another 6 tumor-bearing mice were treated intraperitoneally with 5-FU (75 mg/kg). Blood samples were obtained from orbital venous sinus on different days before and after 5-FU treatment, and then complete blood counts were performed and the relationship between the alterations of blood counts and tumor shrinkage after 5-FU treatment was analyzed. RESULTS: Tumor sizes decreased steadily and tumors disappeared within the first week after 5-FU treatment; and at the same time 75 mg/kg 5-FU also had side effects on peripherial blood cells. The number of WBC significantly decreased from the first day after 5-FU treatment (P<0.001). But during the 7 th to 15 th day the number of WBC rebounced back to normal level (P>0.05). Later it decreased again and it couldn't recover back to normal level at the 28th day after 5-FU treatment (P<0.01). The concentration of Hb decreased at the first day and lasted for 2 weeks (P<0.01). It increased gradually back to normal in 2 weeks after 5-FU treatment. The inhibitory effect of 5-FU on platelets count was not obvious. The platelet count increased significantly at the first and at the 11th day after 5-FU treatment respectively (P<0.01). CONCLUSION: Tumor shrinkage after 5-FU treatment is not related to the decreased number of WBC or RBC, but correlated with the increased number of platelet at the first day after 5-FU treatment.
Assuntos
Antimetabólitos Antineoplásicos/uso terapêutico , Fluoruracila/uso terapêutico , Linfoma/tratamento farmacológico , Linfoma/patologia , Animais , Plaquetas/efeitos dos fármacos , Linhagem Celular Tumoral , Modelos Animais de Doenças , Eritrócitos/efeitos dos fármacos , Feminino , Leucócitos/efeitos dos fármacos , Linfoma/sangue , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Distribuição AleatóriaRESUMO
OBJECTIVE: To investigate the toxicity attenuation and efficacy potentiation effects of Sijunzi decoction (SJZD) on bladder carcinoma treated by chemotherapy in mice. METHODS: T739 mice were randomly divided into 8 groups after subcutaneous inoculation of bladder carcinoma cells, the control group (A); two mitomycin C (MMC) group, treated with MMC of routine dosage (B) and low-dosage (C) respectively; three SJZD groups, treated with SJZD of high (D), medium (E) and low-dosage (F) respectively; and two combined treatment groups, treated with SJZD of high-dosage + MMC of routine dosage(G) and SJZD of high-dosage + MMC of low-dosage(H). The medication was begun at 24 hrs after inoculation. The tumor inhibitory rate, activity of peritoneal macrophages after 14 days of treatment and change of peripheral white blood cells after 7 days of treatment were determined and the survival time of mice was observed. RESULTS: The survival time of mice in Group D was significantly higher than that in Group A (P < 0.05), while those in Group E and F showed insignificant difference as compared with those in Group A (P > 0.05). The highest tumor inhibitory rate was shown in Group B, but the survival time in that group showed no significant difference as compared to those in Group A (P > 0.05). The longest survival time (32.7 +/- 1.3 days) was shown in Group H, which was obviously different to that in other groups (P < 0.05). And the leukocyte counts and macrophage activity in Group H were better than those in Group B, C and G (P < 0.05), except that the tumor inhibitory rate was significantly lower than that in Group B, C and G (P < 0.05). CONCLUSION: Combined chemotherapy of SJZD with low dosage MMC has definite effect in inhibiting tumor growth in mice with bladder carcinoma, displaying special effects of toxicity attenuation and efficacy potentiation.